Tesamorelin - Biologic Drug Details

Summary for tesamorelin

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tesamorelin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tesamorelin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Theratechnologies Inc.	EGRIFTA	tesamorelin	For Injection	022505			DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA	tesamorelin	For Injection	022505			DrugPatentWatch analysis and company disclosures
Theratechnologies Inc.	EGRIFTA	tesamorelin	For Injection	022505			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for tesamorelin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Theratechnologies Inc.	EGRIFTA	tesamorelin	For Injection	022505		2034-05-02	Patent claims search
Theratechnologies Inc.	EGRIFTA	tesamorelin	For Injection	022505		2031-06-03	Patent claims search
Theratechnologies Inc.	EGRIFTA SV	tesamorelin	For Injection	022505		2034-05-02	Patent claims search

International Patents for tesamorelin

Country	Patent Number	Estimated Expiration
Japan	7427419
Brazil	112015027297
Canada	2910584

Tesamorelin Market Analysis and Financial Projection

Last updated: February 16, 2026

Market Dynamics and Financial Trajectory for Tesamorelin

Overview

Tesamorelin is a synthetic peptide that stimulates growth hormone (GH) release, primarily used to reduce excess abdominal fat in HIV-associated abdominal adiposity. Approved by the U.S. Food and Drug Administration (FDA) in 2013 under the brand name Egrifta, its commercial potential hinges on HIV patient management and potential off-label uses.

Current Market Landscape

U.S. Market Size and Prescription Trends

In 2022, Egrifta's annual U.S. sales hovered around $25 million, reflecting limited adoption. The drug's niche status stems from its specific indication and the relatively small HIV-positive population with treatment-related lipodystrophy, estimated at approximately 200,000 individuals [1].

Prescription volumes have remained stable, with fluctuations driven by:

• Awareness campaigns among healthcare providers
• Updates in HIV management protocols
• Pricing and reimbursement policies

Competitive Environment

No direct alternatives are FDA-approved for HIV-associated lipodystrophy. Off-label use of growth hormone or other lipodystrophy treatments exists but lacks standardized approval. The absence of close competitors sustains Egrifta’s market, but new therapies or broader indications could impact its standing.

Growth Drivers

Expanded Indications

Potential off-label or investigational uses include:

• Non-alcoholic fatty liver disease (NAFLD)
• Aging-related growth hormone deficiency
• Muscle wasting conditions

Regulatory approval for these indications could disrupt the current market size.

Patent and Regulatory Landscape

Egrifta’s initial patent defenses expired in 2021, opening the pathway for biosimilars. This could lead to price competition, potentially eroding margins unless new formulations or indications are secured.

Future Financial Trajectory

Revenue Projections

Assuming modest growth through expanded indications or increased prescriber acceptance, sales could reach $35-$50 million annually within five years. Price stability or marginal increases are assumed, barring biosimilar entry.

Pricing Strategies

Egrifta's current wholesale acquisition cost (WAC) approximates $6,000 per month. Price reductions may occur in response to biosimilar competition, pressure from payers, and market dynamics.

Cost and Investment Outlook

Development of indications like NAFLD or aging-related muscle loss involves clinical trials with estimated costs of $50-$100 million per indication. Achieving regulatory approval could extend timelines by 3-5 years, influencing revenue forecasts.

Risks and Opportunities

Risks	Opportunities
Biosimilar competition reduces pricing	Approval for broader indications increases market size
Limited awareness among healthcare providers	Strategic partnerships with specialty clinics
Slow enrollment or regulatory delays	Orphan status incentives for new indications

Strategic Considerations

• Partnering with biotech firms developing growth hormone-related therapies could create synergies.
• Intellectual property rights on formulation improvements or delivery systems may prolong market exclusivity.
• Payers’ approval policies, especially cost-effectiveness assessments, influence patient access and revenue.

---

Key Takeaways

• Egrifta's sales remain limited, constrained by its niche indication and small patient population.
• Growth relies on expanded indications, biosimilar competition, and increased prescriber awareness.
• Development costs for new indications range from $50 million to $100 million, with clinical timelines extending 3 to 5 years.
• Patent expirations and biosimilar entries threaten pricing and profit margins.
• Strategic efforts should focus on broader indications, partnerships, and maintaining market exclusivity.

---

FAQs

1. What is the primary indication for tesamorelin?
It is approved for reducing abdominal fat in HIV-infected patients with lipodystrophy.

2. Can tesamorelin be used for other conditions?
While off-label uses exist, regulatory approval has been limited to HIV-associated lipodystrophy. Investigational uses include NAFLD and aging-related muscle wasting.

3. How is the competitive landscape expected to change?
Biosimilar entries following patent expiry may increase competition and reduce prices. No major new branded competitors are currently active.

4. What are the main barriers to market expansion?
Limited awareness among clinicians, small patient population, high development costs for new indications, and potential reimbursement hurdles.

5. What strategies could sustain or grow revenues?
Securing approval for additional indications, forming strategic partnerships, and developing proprietary formulations to extend exclusivity.

---

References

[1] IQVIA, 2022. U.S. Prescription Data for Egrifta.